Standard BioTools Inc. Operating Expenses
Standard BioTools Inc. (LAB) reported Operating Expenses of $35.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Standard BioTools Inc. operating expenses for the quarter ending 2026-06-30 was $35.92M, a 1.11% decline year-over-year.
- Standard BioTools Inc. operating expenses for the quarter ending 2026-03-31 was $23.80M, a 37.39% decline year-over-year.
- Standard BioTools Inc. operating expenses for the quarter ending 2025-12-31 was $36.03M, a 3.77% decline year-over-year.
- Standard BioTools Inc. operating expenses for the quarter ending 2025-09-30 was $42.42M, a 9.26% increase year-over-year.
- Standard BioTools Inc. operating expenses for fiscal 2025 was $152.79M, a 11.36% decline from fiscal 2024.
- Standard BioTools Inc. operating expenses for fiscal 2024 was $172.37M, a 35.67% increase from fiscal 2023.
- Standard BioTools Inc. operating expenses for fiscal 2023 was $127.05M, a 17.10% decline from fiscal 2022.
- Standard BioTools Inc. operating expenses for fiscal 2022 was $153.26M, a 22.61% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $35.92M 10-Q · filed 2026-08-05 | $59.73M 10-Q · filed 2026-08-05 | $95.75M derived: sum of 3 quarters · filed 2026-08-05 | $138.18M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $23.80M 10-Q · filed 2026-05-06 | $59.83M derived: sum of 2 quarters · filed 2026-05-06 | $102.25M derived: sum of 3 quarters · filed 2026-05-06 | $138.58M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $36.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $78.45M derived: sum of 2 quarters · filed 2026-03-16 | $114.77M derived: sum of 3 quarters · filed 2026-08-05 | $152.79M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $42.42M 10-Q · filed 2025-11-04 | $78.75M derived: sum of 2 quarters · filed 2026-08-05 | $116.77M 10-Q · filed 2025-11-04 | $154.21M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $36.33M 10-Q · filed 2026-08-05 | $74.34M 10-Q · filed 2026-08-05 | $111.78M derived: sum of 3 quarters · filed 2026-08-05 | $150.61M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $38.02M 10-Q · filed 2026-05-06 | $52.71M 10-Q · filed 2025-05-06 | $75.46M derived: sum of 2 quarters · filed 2026-05-06 | $114.28M derived: sum of 3 quarters · filed 2026-05-06 | $154.92M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $37.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $76.26M derived: sum of 2 quarters · filed 2026-03-16 | $116.90M derived: sum of 3 quarters · filed 2026-03-16 | $172.37M 10-K · filed 2026-03-16 | $259.50M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $38.83M 10-Q · filed 2025-11-04 | $54.98M 10-Q · filed 2024-11-06 | $79.46M derived: sum of 2 quarters · filed 2025-11-04 | $134.93M 10-Q · filed 2025-11-04 | $204.78M 10-Q · filed 2024-11-06 | $198.57M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-06-30 | $40.63M 10-Q · filed 2025-08-15 | $65.43M 10-Q · filed 2024-08-06 | $96.10M 10-Q · filed 2025-08-15 | $149.80M 10-Q · filed 2024-08-06 | $159.75M derived: sum of 3 quarters · filed 2026-03-16 | $192.07M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-03-31 | $84.37M 10-Q · filed 2025-05-06 | $119.11M derived: sum of 2 quarters · filed 2026-03-16 | $151.44M derived: sum of 3 quarters · filed 2026-03-16 | $182.49M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2023-12-31 | $34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $67.07M derived: sum of 2 quarters · filed 2026-03-16 | $98.12M derived: sum of 3 quarters · filed 2026-03-16 | $127.05M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | $32.33M 10-Q · filed 2024-11-06 | $63.38M derived: sum of 2 quarters · filed 2024-11-06 | $92.31M 10-Q · filed 2024-11-06 | $124.53M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | $31.05M 10-Q · filed 2024-08-06 | $59.92M 10-Q · filed 2024-08-06 | $59.98M 10-Q · filed 2023-08-08 | $92.20M derived: sum of 3 quarters · filed 2025-03-11 | $130.45M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2023-03-31 | $28.87M 10-Q · filed 2024-05-09 | $41.71M 10-Q · filed 2023-05-09 | $61.15M derived: sum of 2 quarters · filed 2025-03-11 | $99.40M derived: sum of 3 quarters · filed 2025-03-11 | $142.39M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2022-12-31 | $32.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $70.53M derived: sum of 2 quarters · filed 2025-03-11 | $113.52M derived: sum of 3 quarters · filed 2025-03-11 | $153.26M 10-K · filed 2025-03-11 | $214.15M 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $38.25M 10-Q · filed 2023-11-07 | $54.67M 10-Q · filed 2022-11-09 | $81.24M derived: sum of 2 quarters · filed 2023-11-07 | $120.98M 10-Q · filed 2023-11-07 | $166.02M 10-Q · filed 2022-11-09 | $184.77M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $42.99M 10-Q · filed 2023-08-08 | $57.34M 10-Q · filed 2022-08-09 | $82.73M 10-Q · filed 2023-08-08 | $111.35M 10-Q · filed 2022-08-09 | $146.52M derived: sum of 3 quarters · filed 2023-08-08 | $194.64M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $54.01M 10-Q · filed 2023-05-09 | $103.53M derived: sum of 2 quarters · filed 2023-05-09 | $151.65M derived: sum of 3 quarters · filed 2023-05-09 | $199.93M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $49.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $97.64M derived: sum of 2 quarters · filed 2023-03-14 | $145.93M derived: sum of 3 quarters · filed 2023-03-14 | $198.04M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $48.12M 10-Q · filed 2022-11-09 | $96.40M derived: sum of 2 quarters · filed 2022-11-09 | $148.52M 10-Q · filed 2022-11-09 | $210.03M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $48.29M 10-Q · filed 2022-08-09 | $100.40M 10-Q · filed 2022-08-09 | $161.91M derived: sum of 3 quarters · filed 2022-08-09 | $207.24M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $52.11M 10-Q · filed 2022-05-09 | $113.63M derived: sum of 2 quarters · filed 2022-05-09 | $158.95M derived: sum of 3 quarters · filed 2022-05-09 | $198.74M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $61.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $106.84M derived: sum of 2 quarters · filed 2022-03-08 | $146.62M derived: sum of 3 quarters · filed 2022-03-08 | $189.18M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $45.33M 10-Q · filed 2021-11-09 | $85.11M derived: sum of 2 quarters · filed 2021-11-09 | $127.67M 10-Q · filed 2021-11-09 | $169.29M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2020-06-30 | $39.78M 10-Q · filed 2021-08-06 | $82.34M 10-Q · filed 2021-08-06 | $123.96M derived: sum of 3 quarters · filed 2022-03-08 | $164.28M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2020-03-31 | $42.56M 10-Q · filed 2021-05-07 | $84.18M derived: sum of 2 quarters · filed 2022-03-08 | $124.49M derived: sum of 3 quarters · filed 2022-03-08 | $167.32M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2019-12-31 | $41.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $81.93M derived: sum of 2 quarters · filed 2022-03-08 | $124.77M derived: sum of 3 quarters · filed 2022-03-08 | $169.08M 10-K · filed 2022-03-08 | $116.12M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $40.31M 10-Q · filed 2020-11-09 | $83.14M derived: sum of 2 quarters · filed 2020-11-09 | $127.46M 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | $42.83M 10-Q · filed 2020-08-07 | $87.15M 10-Q · filed 2020-08-07 | ||||||
| 2019-03-31 | $44.32M 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | $161.13M 10-K · filed 2021-02-25 | $109.81M 10-K · filed 2019-03-18 | ||||||
| 2017-12-31 | $110.34M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $131.63M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |